<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of the present study was to investigate the protective effect of various doses of exogenous vasopressin (AVP) against <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion injury in anesthetized rat heart </plain></SENT>
<SENT sid="1" pm="."><plain>Anesthetized rats were randomly divided into seven groups (n=4-13) and <z:hpo ids='HP_0000001'>all</z:hpo> of them subjected to prolonged 30 min regional <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and 120 min reperfusion </plain></SENT>
<SENT sid="2" pm="."><plain>Group I served as saline control with <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, in treatment groups II, III, IV and V, respectively different doses of AVP (0.015, 0.03, 0.06 and 1.2 μg/rat) were infused within 10 min prior to <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, in group VI, an AVP-selective V1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> (SR49059, 1mg/kg, i.v.) was administrated prior to effective dose of AVP injection and in group VII, SR49059 (1 mg/kg, i.v.) was only administrated prior to <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Various doses of AVP significantly prevented the decrease in heart rate (HR) at the end of reperfusion compared to their baseline and decreased <z:mpath ids='MPATH_124'>infarct</z:mpath> size, biochemical parameters [LDH (<z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase), CK-MB (<z:chebi fb="2" ids="16919">creatine</z:chebi> kinase-MB) and <z:chebi fb="14" ids="32506">MDA</z:chebi> (malondialdehyde) plasma levels], severity and incidence of <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo>, episodes and duration of <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (VT) as compared to control group </plain></SENT>
<SENT sid="4" pm="."><plain>Blockade of V1 receptors by SR49059 attenuated the cardioprotective effect of AVP on <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> and biochemical parameters, but partially returned <z:mpath ids='MPATH_124'>infarct</z:mpath> size to control </plain></SENT>
<SENT sid="5" pm="."><plain>AVP 0.03 μg/rat was known as effective dose </plain></SENT>
<SENT sid="6" pm="."><plain>Our results showed that AVP owns a cardioprotective effect probably via V1 receptors on cardiac myocyte against <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion injury in rat heart in vivo </plain></SENT>
</text></document>